From: A three-gene expression-based risk score can refine the European LeukemiaNet AML classification
ELN risk | TriAS | Number of patients | 3-year OS (%) | Median OS (days) | Refined ELN + TriAS |
---|---|---|---|---|---|
Favorable | 1 | 24 | 77.4 | Not reached | Favorable |
Favorable | 2 | 59 | 75.4 | 3555 | Favorable |
Intermediate 1/2 | 1 | 7 | 68.6 | Not reached | Favorable |
Favorable | 3 | 46 | 58.1 | 1805 | Intermediate |
Favorable | 4 | 12 | 52.1 | Not reached | Intermediate |
Intermediate 1/2 | 2 | 54 | 50.9 | 1193 | Intermediate |
Adverse | 1 | 2 | 50.0 | Not reached | Intermediate |
Intermediate 1/2 | 3 | 78 | 25.6 | 366 | Adverse |
Intermediate 1/2 | 4 | 22 | 23.9 | 214 | Adverse |
Adverse | 2 | 24 | 21.4 | 368 | Adverse |
Adverse | 3 | 30 | 18.2 | 347 | Adverse |
Adverse | 4 | 17 | 0.0 | 214 | Adverse |